sequella.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | Sequella |
| Description | Welcome to Company Overview Science Product Pipeline Media Center --> --> Latest News Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 fo |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 206.188.192.194 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
sequella.com Valuation
|
US$3,369,940
Last updated: 2023-05-08 23:07:58
sequella.com has Semrush global rank of 3,140,799. sequella.com has an estimated worth of US$ 3,369,940, based on its estimated Ads revenue. sequella.com receives approximately 388,840 unique visitors each day. Its web server is located in United States, with IP address 206.188.192.194. According to SiteAdvisor, sequella.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$3,369,940 |
| Daily Ads Revenue | US$3,111 |
| Monthly Ads Revenue | US$93,322 |
| Yearly Ads Revenue | US$1,119,857 |
| Daily Unique Visitors | 25,923 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| sequella.com. | A | 7199 | IP: 206.188.192.194 |
| sequella.com. | NS | 7200 | NS Record: ns44.worldnic.com. |
| sequella.com. | NS | 7200 | NS Record: ns43.worldnic.com. |
| sequella.com. | MX | 7200 | MX Record: 15 east.smtp.mx.exch082.serverdata.net. |
| sequella.com. | MX | 7200 | MX Record: 20 west.smtp.mx.exch082.serverdata.net. |
HtmlToTextCheckTime:2023-05-08 23:07:58
| Company Overview Science Product Pipeline Media Center --> --> Latest News Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis Release Sequella Acquires Exclusive Worldwide Rights to Pfizer’s Sutezolid, Currently in Clinical Development for Tuberculosis Release Sequella’s Lead Antitubercular Drug Candidate SQ109 Begins Phase 2b Clinical Trial in Africa Release Maxwell Biotech Venture Fund’s Portfolio Company, Infectex, Enrolls First Multi-Drug Resistant Tuberculosis (MDR-TB) Patients in Pivotal Clinical Trial of SQ109, Licensed from Sequella Release LabCorp Enters Into License Agreement with Sequella for use of B-SMART™ Technology to develop Rapid Tuberculosis Antimicrobial Susceptibility Test Release Welcome to Sequella Sequella is a clinical-stage pharma company that develops new and better antibiotics to address drug resistant bacterial, fungal, and parasitic infections. The company’s product |
HTTP Headers
HTTP/1.1 200 OK Server: openresty/1.17.8.2 Date: Sat, 30 Oct 2021 20:42:23 GMT Content-Type: text/html Content-Length: 7895 Connection: keep-alive Vary: Accept-Encoding Last-Modified: Mon, 27 Mar 2017 18:21:55 GMT ETag: "1ed7-54bba6b120a1a" X-Webcom-Cache-Status: BYPASS Accept-Ranges: bytes |
sequella.com Whois Information
Domain Name: SEQUELLA.COM Registry Domain ID: 1497544_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.networksolutions.com Registrar URL: http://networksolutions.com Updated Date: 2021-08-23T15:48:57Z Creation Date: 1997-12-05T05:00:00Z Registry Expiry Date: 2026-12-04T05:00:00Z Registrar: Network Solutions, LLC Registrar IANA ID: 2 Registrar Abuse Contact Email: abuse@web.com Registrar Abuse Contact Phone: +1.8003337680 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS43.WORLDNIC.COM Name Server: NS44.WORLDNIC.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-18T07:00:30Z <<< |